Trigemina Stock

Trigemina develops non-opiate drug formulations and delivery systems for pain therapy.

Sign up today and learn more about Trigemina Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Trigemina Stock

Trigemina, Inc. develops non-opiate drug formulations and delivery systems for the pain therapy. The company’s products include TI-001, an intranasal oxytocin that targets chronic and sub-acute head pain; and TI-002, a non-opioid treatment that addresses a range of pain, including neuropathic pain throughout the body. Its drugs are delivered via the nasal-cerebral pathway. The company was founded in 2006 and is based in Mountain View, California.

Funding History

December 2006$2.0M
December 2009$305K
October 2010$400K
April 2014$8.0M
June 2015$10.0M
July 2017$2.4M


Chief Medical Officer

Shashidhar Kori


Martin Angst


William Frey II

Chief Medical Advisor

Stephen Silberstein

Founder, Chief Scientist

David C Yeomans


Charles Yeomans

Chief Financial Officer & Chief Operating Officer

Michael Leonard

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: